Baidu
map

JAMA OHNS:治疗方式对晚期喉癌的生存率产生差异?

2014-12-02 MedSci译 MedSci原创

喉癌是头颈部肿瘤中相当常见的一类,在美国每年约发生10000例。在中国北方发病率较高,年发病率约0.3~2.03/10万人次。自1887年Billroth做了第1例喉切除术以来已有一百多年历史,手术治疗喉癌具有疗程短、治愈率高等优点,至今仍是治疗喉癌的主要手段。但手术致使患者失去部分或全部喉部组织,造成发声有一定困难。喉全切除者完全丧失发音功能和改变了正常呼吸通道。近几十年来,很多学者主张做喉部分

喉癌是头颈部肿瘤中相当常见的一类,在美国每年约发生10000例。在中国北方发病率较高,年发病率约0.3~2.03/10万人次。自1887年Billroth做了第1例喉切除术以来已有一百多年历史,手术治疗喉癌具有疗程短、治愈率高等优点,至今仍是治疗喉癌的主要手段。但手术致使患者失去部分或全部喉部组织,造成发声有一定困难。喉全切除者完全丧失发音功能和改变了正常呼吸通道。


近几十年来,很多学者主张做喉部分切除术,严格掌握手术适应症则可在保留喉发音、呼吸及吞咽功能的情况下根除病变。而对于晚期喉癌的治疗,在过去的二十年中,主要治疗方式从手术完全切除过渡到保留器官的手术治疗与化疗和放疗。 

在一个单一教学中心的小样本研究中发现,该中心的晚期喉癌患者的5年生存率比全国的平均水平高。对于喉癌的治疗,尽管在全国范围内倾向于对器官的保留,该中心较高比例上实行手术治疗,包括声门的切除。该研究结果报道在近日的 JAMA Otolaryngology-Head & Neck Surgery上。

Blake博士是路易斯安那州立大学位于什里夫波特的健康中心(LSU健康中心)的研究人员,他与其合作者在该机构中对首次手术治疗的晚期喉癌患者的生存率进行了统计分析,并与国家癌症数据库(NCDB)中相对应的结果进行比较。

入组的165例患者(多数是男性,平均年龄55岁)为1998到2007间在LSU健康中心进行肿瘤登记的喉癌患者,其中包括48例(占29.09%)临床早期(I/II期)喉癌和117例(占70.91%)晚期(III /IV期)喉癌。在117例晚期喉癌中,64例(54.70%)接受了初次手术治疗,包括全喉切除或咽喉切除(切除口咽后方的声门及附近区域)。NCDB的数据显示,喉切除术在全国范围内的实行率下降,从20世纪80年代的60%下降至2007年的32%。在LSU健康中心治疗的Ⅳ期喉癌患者的5年生存率为55.54%,相比之下,全国Ⅳ期喉癌患者的5年生存率平均为31.60%。LSU健康中心喉癌患者的整体存活率为59.14%,与全国范围中同期的比例相当。

“这项研究表明,在LSU健康中心治疗的晚期喉癌患者中,有很高比例的人有较低的社会经济地位,但对比研究同期的NCDB中的数据,生存率却取得部分的提高。”该研究作者表示,“这与越来越多文献的报道相似,对比保留器官的治疗方式,晚期喉癌的初次手术治疗可能增加存活率。”

原始出处:

Blake Joseph LeBlanc, Runhua Shi, Vikas Mehta, Glenn Mills, Federico Ampil, Cherie-Ann O. Nathan. Improvements in Survival and Disparities for Advanced-Stage Laryngeal Cancer. JAMA Otolaryngology–Head & Neck Surgery, 2014; DOI: 10.1001/jamaoto.2014.2998.

本文是MedSci原创编译整理,欢迎转载!转载请注明来源并附原文链接。谢谢!

您还可以这样阅读,更多资讯,请关注MedSci微信

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=67141, encodeId=736b6e141d4, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=707b1664677, createdName=不再犹豫, createdTime=Fri Mar 04 08:22:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975778, encodeId=15ed19e5778e3, content=<a href='/topic/show?id=fdbc6464eb2' target=_blank style='color:#2F92EE;'>#治疗方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64647, encryptionId=fdbc6464eb2, topicName=治疗方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 13 19:10:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256497, encodeId=68b7125649e85, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Dec 04 05:10:00 CST 2014, time=2014-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360780, encodeId=c85b1360e80ea, content=<a href='/topic/show?id=795a4012140' target=_blank style='color:#2F92EE;'>#喉癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40121, encryptionId=795a4012140, topicName=喉癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Thu Dec 04 05:10:00 CST 2014, time=2014-12-04, status=1, ipAttribution=)]
    2016-03-04 不再犹豫

    学习啦

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=67141, encodeId=736b6e141d4, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=707b1664677, createdName=不再犹豫, createdTime=Fri Mar 04 08:22:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975778, encodeId=15ed19e5778e3, content=<a href='/topic/show?id=fdbc6464eb2' target=_blank style='color:#2F92EE;'>#治疗方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64647, encryptionId=fdbc6464eb2, topicName=治疗方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 13 19:10:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256497, encodeId=68b7125649e85, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Dec 04 05:10:00 CST 2014, time=2014-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360780, encodeId=c85b1360e80ea, content=<a href='/topic/show?id=795a4012140' target=_blank style='color:#2F92EE;'>#喉癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40121, encryptionId=795a4012140, topicName=喉癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Thu Dec 04 05:10:00 CST 2014, time=2014-12-04, status=1, ipAttribution=)]
    2015-03-13 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=67141, encodeId=736b6e141d4, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=707b1664677, createdName=不再犹豫, createdTime=Fri Mar 04 08:22:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975778, encodeId=15ed19e5778e3, content=<a href='/topic/show?id=fdbc6464eb2' target=_blank style='color:#2F92EE;'>#治疗方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64647, encryptionId=fdbc6464eb2, topicName=治疗方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 13 19:10:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256497, encodeId=68b7125649e85, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Dec 04 05:10:00 CST 2014, time=2014-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360780, encodeId=c85b1360e80ea, content=<a href='/topic/show?id=795a4012140' target=_blank style='color:#2F92EE;'>#喉癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40121, encryptionId=795a4012140, topicName=喉癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Thu Dec 04 05:10:00 CST 2014, time=2014-12-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=67141, encodeId=736b6e141d4, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=707b1664677, createdName=不再犹豫, createdTime=Fri Mar 04 08:22:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975778, encodeId=15ed19e5778e3, content=<a href='/topic/show?id=fdbc6464eb2' target=_blank style='color:#2F92EE;'>#治疗方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64647, encryptionId=fdbc6464eb2, topicName=治疗方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 13 19:10:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256497, encodeId=68b7125649e85, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Dec 04 05:10:00 CST 2014, time=2014-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360780, encodeId=c85b1360e80ea, content=<a href='/topic/show?id=795a4012140' target=_blank style='color:#2F92EE;'>#喉癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40121, encryptionId=795a4012140, topicName=喉癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Thu Dec 04 05:10:00 CST 2014, time=2014-12-04, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map